Press Releases Revvity, Inc.

Equities

RVTY

US7140461093

Market Closed - Nyse Other stock markets 04:00:02 2024-05-31 pm EDT			5-day change	1st Jan Change
109.3 ^USD	+0.85%		-3.54%	-0.05%

May. 14	Transcript : Revvity, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:40 AM
Apr. 30	TD Cowen Adjusts Price Target on Revvity to $130 From $123	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Revvity to Present at Goldman Sachs Global Healthcare Conference	May. 28	BU
Revvity : Q1 2024 Earnings Transcript	Apr. 30	PU
Revvity: Q1 Earnings Snapshot	Apr. 29	AQ
Revvity Announces Financial Results for the First Quarter of 2024	Apr. 29	BU
Revvity Board Declares Quarterly Dividend	Apr. 25	BU
Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings	Apr. 25	AQ
Revvity to Present at BofA Securities 2024 Health Care Conference	Apr. 25	BU
Revvity Unveils a New Era of Automated Tuberculosis Testing	Apr. 24	BU
Revvity Signals Software's New Synergy Solution Redefines Collaboration between Pharma and Contract Partners	Apr. 16	AQ
Revvity Signals Software’s New Synergy Solution Redefines Collaboration Between Pharma and Contract Partners	Apr. 15	BU
Revvity To Hold Earnings Call on Monday, April 29, 2024	Apr. 04	BU
Preliminary Injunction Granted to Enforce Revvity s Rights and Cloud Software Group s Obligations Related to Spotfire Software	Apr. 03	AQ
Preliminary Injunction Granted to Enforce Revvity’s Rights and Cloud Software Group’s Obligations Related to Spotfire Software	Apr. 02	BU
Revvity Files Complaint and Seeks Injunctive Relief Against Cloud Software Group	Mar. 20	BU
Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication	Mar. 18	BU
Revvity : Notice of Annual Meeting and Proxy Statement 2024	Mar. 13	PU
Revvity to Present at Upcoming Investor Conferences	Feb. 21	BU
Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions	Feb. 12	BU
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2023	Feb. 01	BU
Revvity Elects Sophie Vandebroek and Michael Klobuchar to its Board of Directors	Jan. 25	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Revvity, Inc.

Equities

RVTY

US7140461093

Press Releases

Filters